With a rich 300 million market cap to drag it down, this company is going nowhere until it has millions in drug sales. And, as of right now, Ropren isn't even in Phase III trials.
I watch with interest to see what the capital raising price will be. They will have to raise quite a bit to fund the expensive clinical trials, or take on a partner and dilute the company.
The share price has gone up too fast, too soon. Many people are sitting on huge profits, and will take them at the first sniff of trouble. Don't be the last one to turn out the lights.
- Forums
- ASX - By Stock
- SLA
- dilution big risk factor
dilution big risk factor, page-8
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online